Clinical Study of Redirected Autologous T Cells with a BCMA-targeted Chimeric Antigen Receptor in Patients with Refractory or Relapsed Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 29 Dec 2017
At a glance
- Drugs CAR-BCMA-T-cell (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms XHEC-C-2017-027-2
- 31 Aug 2018 Biomarkers information updated
- 15 Dec 2017 Planned End Date changed from 30 Nov 2020 to 30 Sep 2020.
- 15 Dec 2017 Planned primary completion date changed to 30 Sep 2019.